- Conditions
- Nocturia
- Interventions
- Fedovapagon 2 mg, Placebo
- Drug
- Lead sponsor
- Vantia Ltd
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 48
- States / cities
- Anniston, Alabama • Goodyear, Arizona • Lincoln, California + 45 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2665–2688
of 12,245
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Allergic Reaction
- Interventions
- DESF
- Drug
- Lead sponsor
- Aquestive Therapeutics
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 4 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Education worksheet
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Canton, Michigan • Northville, Michigan
- Conditions
- Multiple Myeloma
- Interventions
- Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
- Drug
- Lead sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Chronic Myelomonocytic Leukemia in Remission, Graft Versus Host Disease, Hodgkin Lymphoma, Minimal Residual Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Severe Aplastic Anemia, Waldenstrom Macroglobulinemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan Hydrochloride, Mycophenolate Mofetil, Sirolimus, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Hepatitis B
- Interventions
- Telbivudine (LdT), peginterferon alpha-2a
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Celestra Health Systems
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 90 participants
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Angelman Syndrome
- Interventions
- minocycline
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 4 Years to 12 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Alport Syndrome, Focal Segmental Glomerulosclerosis
- Interventions
- R3R01
- Drug
- Lead sponsor
- River 3 Renal Corp.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Boca Raton, Florida • Miami, Florida + 11 more
- Conditions
- Multiple Sclerosis, Optic Neuritis
- Interventions
- Methylprednisolone, Prednisone
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years to 46 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1988
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • San Francisco, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Acute Myelogenous Leukemia, Lymphoid Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia, Myeloproliferative Disorder, Anemia, Aplastic, Myelodysplastic Syndromes
- Interventions
- Fludarabine, Melphalan, Stem cells, Campath
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- Up to 100 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hematologic Malignancy, Malignant Lymphoma
- Interventions
- Romidepsin, Ketoconazole
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Sarasota, Florida • Nashville, Tennessee
- Conditions
- Allergic Rhinitis, Seasonal Allergic Rhinitis
- Interventions
- Fluticasone propionate, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Multiple Myeloma
- Interventions
- Screening Phase, Discontinuation Phase
- Other · Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Revlimid, Dexamethasone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Step Tracking, Water Tracking
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 30 Years to 59 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Multiple Model Predictive Controller
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 21 Years to 45 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 2
- States / cities
- Stanford, California
- Conditions
- Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Retinal Degeneration, Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 3,549 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2016
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Boston, Massachusetts • Cleveland, Ohio
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Interventions
- Selinexor, Ruxolitinib, Methylprednisolone
- Drug
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- West Hollywood, California
- Conditions
- Multiple Myeloma, Renal Failure
- Interventions
- Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
- Combination Product
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Overweight and Obesity, Type2 Diabetes, NAFLD
- Interventions
- DD01, Placebo
- Drug
- Lead sponsor
- Neuraly, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Chula Vista, California • Fort Myers, Florida • Orlando, Florida
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Pembrolizumab, INBRX-106
- Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Portland, Oregon
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- 3'-deoxy-3'-[18F]fluorothymidine
- Device
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan